Pediatric rheumatology: Strengths and challenges of a new guide for treating JIA

Nature Reviews Rheumatology

Volumn 7, Issue 7, 2011, Pages 377-378

  Hashkes, Philip J ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR INHIBITOR;

ALGORITHM; CHILD SAFETY; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DOCTOR PATIENT RELATION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; HEALTH CARE QUALITY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; PATIENT MONITORING; PEDIATRICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; TREATMENT DURATION; TREATMENT INDICATION; TUBERCULIN TEST;

ALGORITHMS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; HEALTH PLANNING GUIDELINES; HUMANS; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY;

EID: 79959952649     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.67     Document Type: Short Survey

References (10)

1. Beukelman, T. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 63, 465-482 (2011).
2. Lovell, D. J. et al. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res. 63, 10-16 (2011).
3. Hashkes, P. J. & Laxer, R. M. Medical treatment of juvenile idiopathic arthritis. JAMA 294, 1671-1684 (2005). (Pubitemid 41407360)
4. Yokota, S. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371, 998-1006 (2008). (Pubitemid 351389534)
5. Lovell, D. J. et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA) [abstract 2053]. Arthritis Rheum. 60 (Suppl. 10), S768 (2009).
6. Ruperto, N. et al. Evaluation of safety and preliminary efficacy of canakinumab (ACZ885), a new IL-1β blocking monoclonal antibody, in children with systemic juvenile idiopathic arthritis (sJIA) [abstract 2055]. Arthritis Rheum. 60 (Suppl. 10), S769 (2009).
7. Levinson, J. E. & Wallace, C. A. Dismantling the pyramid. J. Rheumatol. 19 (Suppl. 33), 6-10 (1992).
8. Nigrovic, P. A. et al. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63, 545-555 (2011).
9. Foell, D. et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303, 1266-1273 (2010).
10. Diak, P. et al. Tumor necrosis factor α blockers and malignancy in children: forty-eight cases reported to the food and drug administration. Arthritis Rheum. 62, 2517-2524 (2010).